Fibrillar aβ 1-42 vaccine
Fibrillar aβ 1-42 vaccine has been studied in 1 paper since 2016: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Sep 26, 2016: “Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages”.
1 paper studies it2 findingsUpdated
See all 1 papers on fibrillar aβ 1-42 vaccine
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Center for Advancing Translational Sciences and 2 more
- Animals1
What did studies of fibrillar aβ 1-42 vaccine find?
2Studies of fibrillar aβ 1-42 vaccine measured 2 outcomes; the most studied are microhemorrhages (1 study) and brain Aβ (1).
Microhemorrhages
upin dogs1
1 study
Microhemorrhages
upin dogs1
Fibrillar aβ 1-42 vaccine increases microhemorrhages in dogs.
“VAC decreased brain Aβ, pyroglutamate Aβ, increased cerebrospinal fluid Aβ 42 and brain-derived neurotrophic factor RNA levels but also increased microhemorrhages.”
Animalsbrain20 months
Neurobiology of aging
Brain Aβ
downin dogs1
1 study
Brain Aβ
downin dogs1
Fibrillar aβ 1-42 vaccine decreases brain Aβ in dogs.
“VAC decreased brain Aβ, pyroglutamate Aβ, increased cerebrospinal fluid Aβ 42 and brain-derived neurotrophic factor RNA levels but also increased microhemorrhages.”
Animalsbrain20 months
Neurobiology of aging